Faisal Gh. Al-RUBAYE

Serum concentration of Apelin and asymmetric dimethylarginine in hypertensive patients on different modalities of treatment.

Amaç: Hipertansiyon çok önemli bir sağlık sorunudur. Apelin (AP); kardiyovasküler sistemin düzenlenmesinin yanı sıra kan basıncı ve kardiak fonksiyonlarının kontrolünde rol aldığı düşünülen yeni bir multifonksiyonel peptidtir. Mevcut kanıtlar Asimetrik Dimetilarjinin (ADMA)nin nitrik oksit (NO) sentaz inhibitörü ile rekabet halinde olan endojen bir peptit olduğunu göstermektedir. Patofizyolojik konsantrasyonlarda vasküler nitrik oksit (NO) üretimini baskılayan ADMA inhibitörleri bulunmuştur. Fakat esansiyel hipertansiyonda ki ADMA ve apelin seviyeleri ve bunların birbirleriyle olan ilişkileri ve farklı sınıflardan antihipertansif ilaçların endoteliyal fonksiyonları kapsayan bu parametrelerin üzerine olan etkileri hakkında henüz net bir bilgi yoktur. Bu çalışmada esansiyel hipertansiyon tedavisinde kullanılan çeşitli yöntemlerde ki ADMA ve apelinin düzeylerinin değerlendirilmesi amaçlanmıştır. Yöntem: Bu araştırma Al-Yarmouk Eğitim Hastanesinde 2007-2008 yıllarını kapsayan dönemsel bir çalışmadır. Çalışmamız hipertansif hastalarda AP ve ADMA düzeylerinin belirlenmesini içermektedir. 80 hipertansif hasta (G1 ve G2 grupları) bu çalışmaya dahil edilmiş olup uygulanan tedavi metoduna göre sınıflandırılmıştır; kaptopril tedavisi uygulananlar, G1 (n=40); ve atenolol tedavisi uygulananlar, G2 (n=40). Hasta sayısına denk sağlıklı (n=80) bireylerde control grubunu oluşturmuştur. Bulgular: Hipertansif hastalar (G1 ve G2) kontrol grubu (G3) ile kıyaslandığında, serum AP seviyelerinde önemli derecede azalma, serum ADMA seviyelerinde ise önemli oranda yükselme olduğu belirlenmiştir (p< 0.001). Ayrıca hipertansif tedavi metodları; atenolol (G2) ve captopril (G1) uygulanan iki hasta grubu kıyaslandığında bu iki parametre arasında da önemli farklılıklar bulunmuştur (p< 0.001). APnin, ADMA ile negatif bir korelasyon gösterdiği bulunmuştur. (G1 için; r = -0.9, p

Hipertansif hastalara uygulanan farklı tedavi metodlarının apelin (AP) ve asimetrik dimetilarjinin (ADMA) serum konsantrasyonları üzerine etkisinin değerlendirilmesi

Purpose: Hypertension (HTN) is considered a major health problem. Apelin (AP) a novel multifunction peptide implicated in regulation of the cardiovascular system, including blood pressure and cardiac function control, Evidence has accumulated that asymmetric dimethylarginine (ADMA) is an endogenous competitive inhibitor of nitric oxide (NO) synthase. ADMA inhibits vascular NO production at concentrations found in pathophysiological conditions. However, there is no data about ADMA and apelin levels in essential hypertension and any relationship between them and the effect of antihypertensive drugs from various classes on these parameters of endothelial function. The aim of this study is to assess the status of Apelin and Assymetric DiMethyl Arginine in essential Hypertension on various modalities of treatment. Methods: The present study is a cross-sectional study (2007/2008) at Al-Yarmouk Teaching Hospital. Includes measurement of serum AP and ADMA in patients with hypertension. a total of 80 patients with HTN were involved in this study, they were classified according to modality of treatment as Hypertensives on captopril G1: (n=40); Hypertensives on atenolol G2: (n=40). A matching group of eighty apparently healthy volunteers who were included as controls (n=80. Results: Serum AP was significantly reduced and serum ADMA was significantly elevated in hypertensive patients (G1 & G2) as compared with controls (G3) (p < 0.001), also the above significant alteration in these two parameters was found when hypertensives on atenolol (G2) were compared with hypertensives on captopril (G1) (p < 0.001). AP was negatively correlated with ADMA (r = -0.9, p

PDF

___

1. Al-Alwan Aladdin SA , Abou Yousif Z . Iraqi Drug Guide, NBSD & Central Drug Information Burea, Baghdad. 1st edition, 1990; 25.
2. Przewlocka-Kosmala M, Kotwica T, Mysiak A, Kosmala W. Reduced circulating apelin in essential hypertension and its association with cardiac dysfunction. J Hypertens. 2011; 5:971-9.
3. Böger RH. Association of asymmetric dimethylarginine and endothelial dysfunction. Clin Chem Lab Med. 2003; 41:1467-72. PMID: 14656027.
4. Sonmez A, Celebi G, Erdem G, Tapan S, Genc H, Tasci I, Ercin CN, Dogru T, Kilic S, Uckaya G, Yilmaz MI, Erbil MK, Kutlu M.Plasma apelin and ADMA Levels in patients with essential hypertension. Clin Exp Hypertens. 2010; 32:179-83.
5. Instruction manual for Apelin ELISA kit (Phoenix Pharmaceuticals, Inc).
6. Instruction manual for ADMA ELISA kit (Phoenix Pharmaceuticals, Inc).
7. Hajer GR, van Haeften TW, Visseren FL: Adipose tissue dysfunction in obesity, diabetes, and vascular diseases. Eur Heart J. 2008; 29:2959-71.
8. Barak Y, Nelson MC, Ong ES, Jones YZ, Ruiz-Lozano P, Chien KR, Koder A, Evans RM: PPARγ is required for placental, cardiac, and adipose tissue development. Mol Cell. 1999, 4:585-95.
9. Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW Jr: Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest. 2003; 112:1796-1808.
10. Curat CA, Miranville A, Sengenès C, Diehl M, Tonus C, Busse R, Bouloumié A: From blood monocytes to adipose tissue-resident macrophages: induction of diapedesis by human mature adipocytes. Diabetes. 2004; 53:1285-92.
11. Charles CJ: Putative role for apelin in pressure/volume homeostasis and cardiovascular disease. Cardiovasc Hematol Agents Med Chem. 2007; 5:1-10.
12. Kleinz MJ, Skepper JN, Davenport AP: Immunocytochemical localisation of the apelin receptor, APJ, to human cardiomyocytes, vascular smooth muscle and endothelial cells. Regul Pept. 2005; 126:233-40.
13. Salcedo A, Garijo J, Monge L, Fernández N, García-Villalón AL, Sánchez Turrión V, Cuervas-Mons V, Diéguez G: Apelin effects in human splanchnic arteries: role of nitric oxide and prostanoids. Regul Pept. 2007; 144:50-5.
14. Japp AG, Cruden NL, Amer DAB, Li VKY, Goudie EB, Johnston NR, Sharma S, Neilson I, Webb DJ, Megson IL, Flapan AD, Newby DE: Vascular effects of apelin in vivo in man. J Am Coll Cardiol. 2008; 52: 908-13.
15. Gardiner SM, Kemp PA, Bennett T, et al: Regional and cardiac haemodynamic effects of NG, NG,dimethyl-Larginine and their reversibility by vasodilators in conscious rats. Br J Pharmacol. 1993;110:1457-64..
16. Jin JS, DAlecy LG: Central and peripheral effects of asymmetric dimethylarginine, an endogenous nitric oxide synthetase inhibitor. J Cardiovasc Pharmacol. 1996; 28:439-46.
17. White R, Barefield D, Ram S, et al: Peritoneal dialysis solutions reverse the hemodynamic effects of nitric oxide synthesis inhibitors. Kidney Int. 1995; 48:1986-93.
18. Suda O, Tsutsui M, Morishita T, et al: Asymmetric dimethylarginine produces vascular lesions in endothelial nitric oxide synthase-deficient mice: Involvement of reninangiotensin reninangiotensin system and oxidative stress. Arterioscler Thromb Vasc Biol. 2004; 24:1682-88..
19. Sonmez A, Celebi G, Erdem G, Tapan S, Genc H, Tasci I, Ercin CN, Dogru T, Kilic S, Uckaya G, Yilmaz MI, Erbil MK, Kutlu M. Plasma apelin and ADMA Levels in patients with essential hypertension. Clin Exp Hypertens. 2010; 32:179-83.
20. Przewlocka-Kosmala M, Kotwica T, Mysiak A, Kosmala W. Reduced circulating apelin in essential hypertension and its association with cardiac dysfunction. J Hypertens. 2011; 29:971-9.
21. Napoli C, Sica V, de Nigris F, Pignalosa O, Condorelli M, Ignarro LJ, Liguori A. Sulfhydryl angiotensin-converting enzyme inhibition induces sustained reduction of systemic oxidative stress and improves the nitric oxide pathway in patients with essential hypertension. Am Heart J. 2004; 148(1):e5.
22. Ito A, Egashira K, Narishige T, Muramatsu K, Takeshita A. Angiotensin-converting enzyme activity is involved in the mechanism of increased endogenous nitric oxide synthase inhibitor in patients with type 2 diabetes mellitus. Circ J. 2002; 66:811-5.